Background Obesity is associated with thyroid cancer risk. Adiponectin has insulin-sensitizing and anti-inflammatory effects, while progranulin is associated with inflammation and tumorigenesis. We investigated serum adiponectin and progranulin levels in patients with benign thyroid nodule (benign group) and papillary thyroid cancer (PTC; PTC group). The associations between these levels and the clinicopathological features of PTC were evaluated.
Methods We included 157 patients who underwent thyroid surgery (17% of benign and 83% of PTC group). Clinicopathological features including size, lymph node metastasis, extrathyroidal extension (ETE), multifocality, American Thyroid Association risk stratification were evaluated.
Results The age was 42.0 years, and 69% were female. Serum adiponectin and progranulin levels were 6.3 μg/mL and 101.5 ng/mL in the benign group and 5.4 μg/mL and 106.1 ng/mL in the PTC group, respectively (P=0.6 and P=0.4, respectively). Serum adiponectin levels showed no significant differences according to clinicopathological features of PTC. The proportions of patients with primary tumor size >1 cm were 3%, 5%, 8%, and 8% according to serum progranulin level quartiles, respectively (P=0.03). The proportions of patients with microscopic/gross ETE were 8%/0%, 9%/1%, 11%/1%, and 11%/2% according to serum progranulin level quartiles, respectively. Median serum progranulin level was significantly higher in patients with PTC >1 cm than in patients with papillary thyroid microcarcinoma (P=0.04, 115.3 ng/mL and 104.7 ng/mL, respectively).
Conclusion Serum adiponectin and progranulin levels showed no significant difference between benign and PTC groups. Increased serum progranulin levels were significantly associated with PTC >1 cm and microscopic and gross ETE.
Citations
Citations to this article as recorded by
Exploring the logic and conducting a comprehensive evaluation of AdipoRon-based adiponectin replacement therapy against hormone-related cancers—a systematic review Lucas Fornari Laurindo, Andreline Franchi Sosin, Caroline Barbalho Lamas, Ricardo de Alvares Goulart, Jesselina Francisco dos Santos Haber, Claudia Rucco Penteado Detregiachi, Sandra Maria Barbalho Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(4): 2067. CrossRef
Adiponectin Inhibits the Progression of Obesity-Associated Papillary Thyroid Carcinoma Through Autophagy Changlin Li, Jiao Zhang, Gianlorenzo Dionigi, Nan Liang, Haixia Guan, Hui Sun Endocrinology.2024;[Epub] CrossRef
Progranulin Oncogenic Network in Solid Tumors Elisa Ventura, Giacomo Ducci, Reyes Benot Dominguez, Valentina Ruggiero, Antonino Belfiore, Elena Sacco, Marco Vanoni, Renato V. Iozzo, Antonio Giordano, Andrea Morrione Cancers.2023; 15(6): 1706. CrossRef
Obesity and thyroid cancer risk Lauren C. Burrage, Donald S.A. McLeod, Susan J. Jordan Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(5): 244. CrossRef
Progranulin promoted the proliferation, metastasis, and suppressed apoptosis via JAK2-STAT3/4 signaling pathway in papillary thyroid carcinoma Yanxu Dong, Hao Tan, Lidong Wang, Zhen Liu Cancer Cell International.2023;[Epub] CrossRef
Obesity and Thyroid Cancer Risk: An Update Fabiana Franchini, Giuseppe Palatucci, Annamaria Colao, Paola Ungaro, Paolo Emidio Macchia, Immacolata Cristina Nettore International Journal of Environmental Research and Public Health.2022; 19(3): 1116. CrossRef
Obesity and Overweight Are Associated with Minimal Extrathyroidal Extension, Multifocality and Bilaterality of Papillary Thyroid Cancer Krzysztof Kaliszewski, Dorota Diakowska, Marta Rzeszutko, Jerzy Rudnicki Journal of Clinical Medicine.2021; 10(5): 970. CrossRef
Adiponectin and Thyroid Cancer: Insight into the Association between Adiponectin and Obesity Yuanyuan Zhou, Ying Yang, Taicheng Zhou, Bai Li, Zhanjian Wang Aging and disease.2021; 12(2): 597. CrossRef